Welcome to our dedicated page for Oculis Holding news (Ticker: OCS), a resource for investors and traders seeking the latest updates and insights on Oculis Holding stock.
Oculis Holding AG reports news on a late-stage ophthalmology and neuro-ophthalmology pipeline focused on eye and optic-nerve disorders with unmet medical need. Company updates commonly cover OCS-01 eye drops for diabetic macular edema, Privosegtor for optic neuritis and other optic neuropathies, and Licaminlimab, a topical anti-TNFα candidate being developed for dry eye disease with a genotype-based approach.
Recurring developments include clinical-program updates, FDA and EMA regulatory interactions, scientific meeting presentations, pipeline reviews, financial results, capital-market communications, annual general meeting materials, and notifications of managerial transactions. Oculis is a Swiss biopharmaceutical company with ordinary shares traded on Nasdaq and Nasdaq Iceland under OCS.
Oculis (Nasdaq: OCS) and EURETINA have announced Dr. Prithvi Ramtohul as the winner of the 2025 Ramin Tadayoni Award, which honors exceptional postgraduate scholars in retina research. The award, established in 2024, commemorates Professor Ramin Tadayoni, Oculis' former Chief Scientific Officer.
Dr. Ramtohul, an attending physician at Aix-Marseille University Hospital and Ph.D. candidate, is recognized for his contributions to retinal imaging and diseases, with 111 peer-reviewed publications. His research focuses on cellular mechanisms of amblyopia and retinal disease pathophysiology through multimodal imaging analysis.
Oculis (NASDAQ:OCS) announced the vesting and settlement of Restricted Stock Units (RSUs) for director Arshad Khanani. The RSUs were previously granted as part of the company's equity compensation program.
Oculis (NASDAQ: OCS) announced upcoming presentations of clinical trial results at multiple ophthalmology conferences in September 2025. Key highlights include:
The company will present expanded data analysis from Phase 3 Stage 1 DIAMOND program for OCS-01 eye drops in diabetic macular edema (DME), focusing on subgroups by lens status and prior treatment status. Additionally, Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis will be presented in EURETINA's late-breaking session, showing clinically meaningful visual function improvement with anatomical neuroprotection benefits.
Presentations will take place at the Ophthalmology Futures Retina Forum, EURETINA Innovation Spotlight, 25th EURETINA Congress, and Retina Society Annual Congress.
Oculis (Nasdaq: OCS), a global biopharmaceutical company specializing in ophthalmic and neuro-ophthalmic diseases, announced its participation in five major investor conferences during September 2025.
Key presentations include:
- Wells Fargo Healthcare Conference (Sept 3-5, Boston)
- H.C. Wainwright Global Investment Conference (Sept 8-10, New York) - Fireside chat on Sept 8 at 2:30 PM ET
- Baird Global Healthcare Conference (Sept 9-10, New York) - Company update on Sept 9 at 3:45 PM ET
- Pareto Securities Healthcare Conference (Sept 16, Stockholm) - Update at 9:15 AM CET
- Leerink Partners Biopharma Summit (Sept 17-19, Healdsburg)
Oculis (NASDAQ: OCS) has appointed two distinguished medical experts as Chief Medical Advisors. Dr. Mark Kupersmith joins as Chief Medical Advisor for Neuro-Ophthalmology, while Dr. Sebastian Wolf becomes Chief Medical Advisor for Ophthalmology.
The appointments follow significant pipeline progress, including completed enrollment in Phase 3 DIAMOND trials for OCS-01 in diabetic macular edema and positive Phase 2 ACUITY results for Privosegtor (OCS-05) in acute optic neuritis. The company also aligned with FDA on the first genotype-based development program in ophthalmology with Licaminlimab (OCS-02) for dry eye disease.
Topline results for the DIAMOND trials are expected in Q2 2026, with NDA filing planned for 2H 2026.
Oculis (NASDAQ: OCS) reported Q2 2025 financial results and provided updates on its ophthalmology pipeline. The company maintained a cash position of $201.3 million as of June 30, 2025, with runway into early 2028, supplemented by a $123.7 million BlackRock loan facility.
Key pipeline developments include: OCS-01's Phase 3 DIAMOND trials completion of enrollment with over 800 patients for diabetic macular edema treatment, with topline results expected Q2 2026; Privosegtor (OCS-05) advancing to Phase 2/3 trial in acute optic neuritis in 1H 2026 following positive Phase 2 results; and Licaminlimab (OCS-02) preparing for genotype-based Phase 2/3 trial in dry eye disease in 2H 2025.
Financial results showed R&D expenses of $18.1 million for Q2 2025, slightly down from Q2 2024, and a year-to-date net loss of $67.9 million, increased from $41.5 million in the same period 2024.
Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company specializing in ophthalmic and neuro-ophthalmic conditions, announced its participation in the H.C Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025.
Two key presentations are scheduled: CFO Sylvia Cheung will deliver a corporate update available via webcast at 7:00am ET, while R&D President Snehal Shah will participate in a panel discussion on Pivotal-Stage Assets for Retinal Disorders from 11:00am to 12:00pm ET. Both presentations will be accessible for replay through Oculis' website.
Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company specializing in ophthalmic and neuro-ophthalmic conditions, announced its participation in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025.
Two key presentations are scheduled: CFO Sylvia Cheung will deliver a corporate update available via webcast at 7:00 AM ET, while R&D President Snehal Shah will participate in a panel discussion on Pivotal-Stage Assets for Retinal Disorders from 11:00 AM to 12:00 PM ET. Both presentations will be accessible for replay through Oculis' website.
Oculis Holding AG (Nasdaq: OCS) held its 2025 Annual General Meeting on June 4, 2025, where shareholders approved all agenda items. Key approvals included the 2024 Annual Report, which showed a statutory loss of CHF 5.17 million for 2024, and an accumulated balance sheet loss of CHF 46.57 million.
The meeting resulted in the re-election of Anthony Rosenberg as Board Chair and seven other board members. Shareholders approved compensation packages including USD 2.47 million in fixed compensation for executive committee members and a maximum of USD 15.5 million in equity-based compensation. Additionally, shareholders approved a capital band of 27.26 million registered shares and a conditional share capital for employees of up to 12.48 million shares.
Oculis (NASDAQ: OCS) has amended its loan agreement with BlackRock, significantly expanding its borrowing capacity to CHF 75 million, with potential increase to CHF 100 million. The loan comprises three tranches of CHF 25 million each, plus an additional potential CHF 25 million subject to mutual agreement.
The enhanced facility provides financial flexibility beyond current cash reserves as Oculis approaches key milestones, including FDA discussions for Privosegtor in three indications, initiation of Licaminlimab Phase 2/3 trial, and OCS-01 Phase 3 trial results. The company's current cash position extends runway into early 2028.